Similarly, orelabrutinib is a BTK inhibitor for B-cell malignancies and is currently under phase II trial for the treatment of RRMS only,68 ClinicalTrials.gov identifier: NCT04711148. This evidence concerns the gene BTK and relapsing-remitting multiple sclerosis.